Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Study reveals how measles virus mutates and spreads in the human brain December 21, 2023 Targeted Thermal Therapy could transform management of common cause of high blood pressure February 8, 2025 Intensive blood pressure control reduces dementia risk in adults with hypertension November 13, 2023
Targeted Thermal Therapy could transform management of common cause of high blood pressure February 8, 2025